文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

缬沙坦对早期肥厚型心肌病心脏重构的影响:VANISH试验心脏磁共振亚研究

Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance Substudy.
PubMed 文献 · JAMA Cardiol · 2025-01-01

该研究是VANISH随机临床试验的预设心脏磁共振亚研究,纳入137例早期肌节性肥厚型心肌病患者,评估缬沙坦对比安慰剂对心肌结构、功能和组织参数的影响。结果显示缬沙坦可能增加左室舒张末期容积指数、减少右室容积下降,并显著减缓细胞内体积指数进展,但未显著影响左室质量指数、细胞外体积指数或晚期钆增强进展。

要点

  • 缬沙坦可能改善早期肥厚型心肌病患者的双心室重构。
  • 缬沙坦显著减缓心肌细胞内体积指数进展。
  • 缬沙坦对细胞外体积指数和晚期钆增强进展无显著影响。

核心结论

  • 缬沙坦对早期肥厚型心肌病患者的双心室重构和心肌细胞内体积具有潜在益处。
  • 缬沙坦未显著影响左室质量指数、细胞外体积指数或晚期钆增强进展。

研究设计与样本

  • VANISH随机临床试验的预设心脏磁共振亚研究,2014年4月至2019年7月在17个国际中心开展。
  • 纳入137例年龄8至45岁、无症状或症状轻微的早期肌节性肥厚型心肌病患者。

主要发现

  • 缬沙坦可能减缓右室容积下降。

关键数值与推荐

  • 缬沙坦剂量:体重<35 kg儿童80 mg/日,体重≥35 kg儿童160 mg/日,成人(≥18岁)320 mg/日。
  • 主要结局为基线至第2年心脏磁共振参数的平均变化,包括指数化细胞外体积、指数化细胞内体积和晚期钆增强。

临床怎么用

  • 对于早期肌节性肥厚型心肌病患者,缬沙坦可能作为减缓心肌重构的潜在治疗选择。
  • 心脏磁共振组织特征参数可用于监测缬沙坦对心肌重构的效应。

局限性

  • 本研究为VANISH试验的亚研究,样本量有限(137例完成心脏磁共振检查)。
  • 缬沙坦影响肥厚型心肌病进展的细胞机制仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Valsartan has been shown to attenuate phenotypic progression among individuals with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Myocardial tissue characterization by cardiac magnetic resonance (CMR) imaging may enhance mechanistic insights, but whether valsartan influences these parameters remains uncertain. OBJECTIVE: To evaluate the treatment effects of valsartan on myocardial structure, function, and tissue parameters in early-stage sarcomeric HCM. DESIGN, SETTING, AND PARTICIPANTS: This prespecified CMR substudy of the VANISH (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) randomized clinical trial evaluated treatment effects of valsartan vs placebo on myocardial structure, function, and tissue parameters and was conducted from April 2014 through July 2019 at 17 international sites. Individuals aged 8 to 45 years with early-stage HCM aged between 8 and 45 years and with no or minimal symptoms were eligible for inclusion. INTERVENTIONS: Treatment with placebo or valsartan (80 mg per day for children weighing <35 kg, 160 mg per day for children weighing ≥35 kg, or 320 mg per day for adults aged 18 years or older). MAIN OUTCOMES AND MEASURES: The primary outcome was mean change in CMR parameters between baseline and year 2, including indexed extracellular volume (iECV), indexed intracellular volume (iICV), and late gadolinium enhancement (LGE). Mean between-group differences in CMR parameters between baseline and year 2 were evaluated using multivariable mixed-effects linear regression models. RESULTS: Overall, 137 of 178 VANISH participants (77.0%) underwent CMR imaging at baseline and year 2. Among these participants, mean (SD) age was 23 (10) years, and 51 participants (37.2%) were female. Baseline characteristics and CMR parameters were well balanced between treatment groups. Higher LGE, iECV, and iICV at baseline were associated with higher cardiac biomarker levels and more pronounced cardiac remodeling. Between baseline and year 2, valsartan appeared to increase left ventricular (LV) end-diastolic volume index (mean difference [MD], 3.3 mL/m2; 95% CI, 0.4-6.2; P = .03), suggesting treatment benefit, but did not significantly impact LV mass index (MD, -2.9 g/m2; 95% CI, -6.1 to 0.2; P = .07) or LV ejection fraction. Similarly, valsartan appeared to reduce decline in right ventricular volumes. Valsartan appeared to significantly reduce iICV progression (MD, -5.0 mL/m2; 95% CI, -9.7 to -0.4; P = .03), but did not impact iECV (MD, 0.0 mL/m2; 95% CI, -1.4 to 1.3; P = .95) or LGE progression (MD, 0.5%; 95% CI, -0.4 to 1.3; P = .30). CONCLUSIONS AND RELEVANCE: These findings enhance mechanistic insights into the effect of valsartan in early-stage HCM, showing potential benefits on biventricular remodeling and myocardial intracellular volume. Further research to identify cellular mechanisms of valsartan on HCM progression is needed. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01912534.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Ostrominski JW, Claggett BL, Jerosch-Herold M, et al. Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance Substudy. JAMA Cardiol. 2025. PMID: 40042824. doi:10.1001/jamacardio.2024.5677

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。